Genetic Background, Adipocytokines, and Metabolic Disorders in Postmenopausal Overweight and Obese Women

Biochemical Genetics

Volumn 54, Issue 5, 2016, Pages 636-652

  Grygiel Górniak, Bogna ^a   Kaczmarek, Elżbieta ^a   Mosor, Maria ^b   Przysławski, Juliusz ^a   Bogacz, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

Adipocytokines; Body fat distribution; Metabolic disorders; Postmenopausal obesity; PPAR gamma 2 and beta3 AR polymorphism

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE; ARGININE; CHOLESTEROL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROLINE; RESISTIN; TRIACYLGLYCEROL; TRYPTOPHAN; URIC ACID; ADRB3 PROTEIN, HUMAN; BETA 3 ADRENERGIC RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADRB3 GENE; ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC BACKGROUND; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IMPEDANCE; INSULIN BLOOD LEVEL; INTRAPERITONEAL FAT; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MIDDLE AGED; NUTRITIONAL STATUS; OBESITY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PPAR GAMMA 2 GENE; PREVALENCE; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; BODY FAT DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC DISEASES; MIDDLE AGED; OBESITY; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PPAR GAMMA; RECEPTORS, ADRENERGIC, BETA-3;

EID: 84973165817     PISSN: 00062928     EISSN: 15734927     Source Type: Journal    
DOI: 10.1007/s10528-016-9743-z     Document Type: Article

References (48)

1. Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11(8):327–332
2. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257(1):79–83
3. Botella-Carretero JI, Luque-Ramírez M, Alvarez-Blasco F, Peromingo R, San Millán JL, Escobar-Morreale HF (2008) The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg 18(8):1000–1006
4. Burguete-Garcia AI, Martinez-Nava GA, Valladares-Salgado A, Bermudez Morales VH, Estrada-Velasco B, Wacher N, Peralta-Romero J, Garcia-Mena J, Parra E, Cruz M (2014) Association of β1 and β3 adrenergic receptors gene polymorphisms with insulin resistance and high lipid profiles related to type 2 diabetes and metabolic syndrome. Nutr Hosp 29(6):1327–1334
5. Cheung KJ, Tzameli I, Pissios P et al (2007) Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab 5:115–128
6. Cullen P (2000) Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86(9):943–949
7. Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A, Palmer CN (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21
8. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI (2011) Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60(1):63–70
9. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502
10. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430
11. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225–2229
12. García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, Gallego-Perales JL, Rojo-Martínez G, Garrido-Sánchez L, Bermudez-Silva FJ, Rodríguez de Fonseca F, Soriguer F (2007) Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 15(10):2391–2395
13. Green PJ, Silverman BW (1994) Nonparametric regression and generalized linear models: a roughness penalty approach. Chapman & Hall, London
14. Grygiel-Górniak B, Kaczmarek E, Mosor M, Przysławski J, Nowak J (2015) Association of PPAR-γ2 and β3-AR polymorphisms with postmenopausal hypertension. J. Clin. Hypertens (Greenwich) 17:549–556
15. Gu SJ, Guo ZR, Zhou ZY, Hu XS, Wu M, Zhang N (2014) Peroxisome proliferator-activated receptor γ polymorphisms as risk factors for dyslipidemia. Mol Med Rep 10(5):2759–2763
16. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91(4):1578–1581
17. Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T (2007) Relationship between hyperuricemia and body fat distribution. Intern Med 46:1353–1358
18. Hill T, Lewicki P (2007) Statistics: methods and applications. StatSoft, Tulsa
19. Hsueh WC, Cole SA, Shuldiner AR, Beamer BA, Blangero J, Hixson JE, MacCluer JW, Mitchell BD (2001) Interactions between variants in the beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes and obesity. Diabetes Care 24(4):672–677
20. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52(7):1655–1663
21. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glassock RJ, Shimada M, Roncal C, Nakagawa T (2009) Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30(1):96–116
22. Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y (2004) Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 53(12):1538–1543
23. Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, Chatterjee VK, Wareham NJ (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50(3):686–689
24. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9):2094–2099
25. Masud S, Ye S, SAS Group (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40(10):773–780
26. Mayi TH, Duhem C, Copin C, Bouhlel MA, Rigamonti E, Pattou F, Staels B, Chinetti-Gbaguidi G (2010) Visfatin is induced by peroxisome proliferator-activated receptor gamma in human macrophages. FEBS J 277(16):3308–3320
27. Nagaev I, Smith U (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285(2):561–564
28. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR (2001) Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 50(9):2172–2176
29. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL (2007) Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 156(2):279–284
30. Oeveren van-Dybicz AM, Vonkeman HE, Bon MA, van den Bergh FA, Vermes I (2001) Beta 3-adrenergic receptor gene polymorphism and type 2 diabetes in a Caucasian population. Diabetes Obes Metab 3(1):47–51
31. Oizumi T, Daimon M, Saitoh T, Kameda W, Yamaguchi H, Ohnuma H, Igarashi M, Eguchi H, Manaka H, Tominaga M, Kato T, Funagata Diabetes Study (2001) Genotype Arg/Arg, but not Trp/Arg, of the Trp64Arg polymorphism of the beta(3)-adrenergic receptor is associated with type 2 diabetes and obesity in a large Japanese sample. Diabetes Care 249:1579–1583
32. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300(2):472–476
33. Pittas AG, Joseph NA, Greenberg AS (2004) Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89(2):447–452
34. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6(5):363–375
35. Robitaille J, Després JP, Pérusse L, Vohl MC (2003) The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study. Clin Genet 63(2):109–116
36. Rosenquist KJ, Massaro JM, Pedley A, Long MT, Kreger BE, Vasan RS, Murabito JM, Hoffmann U, Fox CS (2015) Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality. J Clin Endocrinol Metab 100(1):227–234
37. Sandeep S, Velmurugan K, Deepa R, Mohan V (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56(4):565–570
38. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O’Rahilly S (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50(10):2199–2202
39. Sivenius K, Valve R, Lindi V, Niskanen L, Laakso M, Uusitupa M (2000) Synergistic effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on long-term body weight change in Finnish type 2 diabetic and non-diabetic control subjects. Int J Obes Relat Metab Disord 24(4):514–519
40. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409(6818):307–312
41. Tamaki S, Nakamura Y, Tabara Y, Okamura T, Kita Y, Kadowaki T, Tsujita Y, Horie M, Miki T, Ueshima H (2006) Relationship between metabolic syndrome and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample: the Shigaraki study. Hypertens Res 29(11):891–896
42. Tokunaga A, Miura A, Okauchi Y, Segawa K, Fukuhara A, Okita K, Takahashi M, Funahashi T, Miyagawa J, Shimomura I, Yamagata K (2008) The-1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J 55(1):205–212
43. Way JM, Görgün CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276(28):25651–25653
44. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86(5):1930–1935
45. WHO (2000) WHO technical report 2000. Obesity: preventing and managing a global epidemic—report of a WHO consultation. WHO, Geneva
46. Yang LL, Hua Q, Liu RK, Yang Z (2009) Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch Med Res 40(2):89–96
47. Yao YS, Li J, Jin YL, Chen Y, He LP (2015) Association between PPAR-γ2 Pro12Ala polymorphism and obesity: a meta-analysis. Mol Biol Rep 42(6):1029–1038
48. Zhou Y, Huang CQ, Lu ZC, Dong BR (2012) Association of serum uric acid with Pro12Ala polymorphism in PPAR-γ2 among Chinese nonagenarians/centenarians. Aging Clin Exp Res 24(2):139–144